Development of a live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a subcutaneous administration of a recombinant canarypoxvirus expressing FELV genes.
EU record number:
Company / Sponsor:
vaccination against feline leukemia virus (FELV)
env and gag genes of the type A virus of feline leukemia (FELV)
Method of transfer of nucleic acid of interest:
Canarypoxvirus (ALVAC clone)
Route of administration:
Locations in Belgium:
Merksem, Heverlee, Mechelen, Deurne, Izegem, Haine St Pierre, Ternat, Overijse, Liège
Nr of subjects:
Type of procedure:
Deliberate release only
Information related to the decision procedure
6 April 1997: The Biosafety Advisory Council a.i. issues a positive advice (with conditions) for this trial.